Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jenny Yang, PharmD
Gilead Sciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
41 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Ottawa, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Auckland, New Zealand
- Facility name not stated
Christchurch, New Zealand
- Facility name not stated
San Juan, Puerto Rico
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Newport Beach, California, United States
- Facility name not stated
Palo Alto, California, United States
- Facility name not stated
Sacramento, California, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
Torrance, California, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
Washington D.C., District of Columbia, United States
- Facility name not stated
Bradenton, Florida, United States
- Facility name not stated
Miami, Florida, United States
- Facility name not stated
Orlando, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Decatur, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Lutherville, Maryland, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Kansas City, Missouri, United States
- Facility name not stated
Santa Fe, New Mexico, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
The Bronx, New York, United States
- Facility name not stated
Chapel Hill, North Carolina, United States
- Facility name not stated
Durham, North Carolina, United States
- Facility name not stated
Cincinnati, Ohio, United States
- Facility name not stated
Allentown, Pennsylvania, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
- Facility name not stated
Providence, Rhode Island, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
Houston, Texas, United States
- Facility name not stated
Annandale, Virginia, United States
- Facility name not stated
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2014
- Primary completion
- 30 Nov 2014
- Completion
- 31 Dec 2015
- Last update posted
- 16 Nov 2018
- Registered enrollment
- 335
- Registry id
- NCT02073656
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.